


# From cyclic polyenes to carbohydrates: synthesis of the hexose sugar $\beta$ -alloose and its 2C-branched homologue from cyclooctatetraene

Goverdhan Mehta\* and Kotapalli Pallavi

Department of Organic Chemistry, Indian Institute of Science, Bangalore 560 012, India

**Abstract**—In an unconventional but interesting synthetic enterprise, the commercially available hydrocarbon cyclooctatetraene (COT) has been elaborated to the rare hexose sugar (DL)- $\beta$ -alloose and its 2C-branched analogue. The synthetic sequence delineated here is notable for its high regio- and stereoselectivity and is flexible enough to enable access to polyoxygenated systems, hexose sugars, and their siblings from a cyclic polyene precursor.


Hexose sugars **1** are among nature's premier and ubiquitous building blocks that are essential for the sustenance of diverse biological systems and processes.<sup>1</sup> Though many hexose sugars are readily available and are plentiful, their architecture with a network of hydroxyl functionalities, and stereochemical nuances has always posed an attractive ongoing challenge to synthetic chemists.<sup>2</sup> During the last few decades, a variety of new and interesting strategies have been developed for the synthesis of hexose sugars and their C-branched siblings. Branched hexose sugars (e.g., **2**) are interesting in their own right as they constitute the glycosidic component of many antibiotics and have also received a great deal of attention from synthetic chemists.<sup>3</sup> While many synthetic approaches to hexose sugars and their branched analogues have been explored,<sup>2,3</sup> the possibility of employing a cyclic polyene like cyclooctatetraene **3** (COT) for their synthesis appealed to us as an esoteric and interesting proposition. Herein, we report the transformation of COT **3** into a rare hexose sugar (DL)- $\beta$ -alloose and its 2C-branched sibling.<sup>4</sup>




Our synthetic approach to hexose sugars emanated from bicyclo[4.2.1]nona-2,4,7-trien-9-one **4**, a 'functionally locked' cyclooctatetraene, readily available from **3** in a single pot operation as described by Shechter and co-workers.<sup>5a</sup> Baeyer–Villiger oxidation of **4** led to the lactone **5** and further catalytic  $\text{OsO}_4$  dihydroxylation, and acetonide protection led to **6** with complete regio- and stereocontrol, Scheme 1.<sup>5b,6</sup> LAH reduction of **6** led to the cyclooctadienediol **7** in which the primary hydroxyl group was selectively protected as the TBS derivative **8**. Ozonolysis of **8** and PCC oxidation of the resulting product led to the bicyclic lactone **10** through the intermediacy of the lactol **9** as depicted in Scheme 1.<sup>6</sup> Methoxide mediated lactone opening in **10** furnished **11** and the anomeric hydroxyl group was protected as the methyl ether **12**. LAH reduction of **12** revealed the branched sugar **13** and further deprotections led to (DL)-methyl-2-deoxy-2C-hydroxymethyl- $\beta$ -alloose **14**. The branched hexose **14** was transformed to the tetraacetate **15** and its X-ray crystal structure determination<sup>7</sup> unambiguously secured its formulation.

Next, the 2C-branched precursor **13** was elaborated to the rare hexose  $\beta$ -alloose. Protection of the C<sub>5</sub>-hydroxymethyl as an acetate **16** and TBS deprotection furnished **17**, Scheme 2.<sup>6</sup> The primary hydroxyl group in **17** was transformed to the terminal olefin **18** via mesylate formation and base mediated elimination. Ozonolysis of **18** furnished the intermediate hemiacetal **19**, which was reduced with sodium borohydride to furnish **20**, Scheme 2.<sup>6</sup> Acetonide deprotection in **20** delivered

\* Corresponding author. Tel.: +91-80-22932850; fax: +91-80-236009-36; e-mail: gm@orgchem.iisc.ernet.in



**Scheme 1.** Reagents and conditions: (a)  $\text{OsO}_4$ , NMMO, 75%; (b) 2,2-dimethoxypropane, acetone, CSA, 65%; (c)  $\text{LiAlH}_4$ , THF, 80%; (d)  $\text{TBSCl}$ , Im, DMF, 54%; (e)  $\text{O}_3$ , DCM–MeOH, DMS; (f) PCC,  $\text{NaOAc}$ , DCM, 40% for two steps; (g)  $\text{NaOMe}$ , MeOH; (h)  $\text{MeI}$ ,  $\text{Ag}_2\text{O}$ , 73% for two steps; (i)  $\text{LiAlH}_4$ , THF, 85%; (j) TBAF, THF, 70%; (k) Amberlyst-15, MeOH, 65%; (l)  $\text{Ac}_2\text{O}$ , py, DMAP, 90%.



**Scheme 2.** Reagents and conditions: (a)  $\text{Ac}_2\text{O}$ , DMAP, DCM, 92%; (b) TBAF, THF, 74%; (c)  $\text{MsCl}$ ,  $\text{Et}_3\text{N}$ , DCM, 65%; (d)  $\text{KO}^\prime\text{Bu}$ , DMSO, 70%; (e)  $\text{O}_3$ , DCM, DMS, 75%; (f)  $\text{NaBH}_4$ , MeOH, 80%; (g) Amberlyst-15, MeOH, 60%.

(**D,L**)-methyl- $\beta$ -alopyranoside **21** whose spectral characteristics were identical with those reported in the literature.<sup>8</sup>

In short, we have accomplished an interesting elaboration of a commercially available polyene (COT) into  $\beta$ -allose and a 2C-branched congener through a strategy that should be amenable for adaptation to access other hexose sugars and some densely oxygenated systems.

### Acknowledgements

This research was supported by the Chemical and Biology Unit of JNCASR, Bangalore, India. One of us (K.P.) would like to thank CSIR (India) for the award of a research fellowship.

### References and notes

- (a) Collins, P. M.; Ferrier, R. J. *Monosaccharides: Their Chemistry and Their Roles in Natural Products*. 1st ed.; Wiley, 1995 (b) Bashkin, J. K. *Chem. Rev.* **2000**, *100*, 4265; (c) Dwek, R. A.; Butters, T. D. *Chem. Rev.* **2002**, *102*, 283.
- (a) Ko, S. Y.; Lee, A. W. M.; Masamune, S.; Reed, L. A., III; Sharpless, K. B.; Walker, F. J. *Science* **1983**, *220*, 949; (b) Vogel, P.; Fattori, D.; Gasparini, F.; Le Drian, C. *Synlett* **1990**, *173*; (c) Hudlicky, T.; Entwistle, D. A.; Pitzer, K. K.; Thorpe, A. *Chem. Rev.* **1996**, *96*, 1195; (d) Takeuchi, M.; Taniguchi, T.; Ogasawara, K. *Synthesis* **1999**, *341*; (e) Taniguchi, T.; Takeuchi, M.; Kadota, K.; ElAzab, A. S.; Ogasawara, K. *Synthesis* **1999**, *1325*; (f) Honzumi, M.; Taniguchi, T.; Ogasawara, K. *Org. Lett.* **2001**, *3*, 1355.
- (a) Yoshimura, J. *Adv. Carbohydr. Chem. Biochem.* **1984**, *42*, 69; (b) Wagner, J.; Vogel, P. *Tetrahedron* **1991**, *47*, 9641; (c) Beyer, J.; Madsen, R. *J. Am. Chem. Soc.* **1998**,


120, 12137; (d) Kato, K.; Yamamura, S. *Nucleosides Nucleotides* **1999**, *18*, 657.

4. (a) Fukami, H.; Koh, H.-S.; Sakata, T.; Nakajima, M. *Tetrahedron Lett.* **1967**, 4771; (b) Brimacombe, J. S.; Hunedy, F.; Husain, A. *J. Chem. Soc. C* **1970**, 1273; (c) Singh, U. P.; Brown, R. K. *Can. J. Chem.* **1971**, *49*, 1179; (d) Dondoni, A.; Fantin, G.; Fogagnolo, M.; Medici, A. *Angew. Chem., Int. Ed. Engl.* **1986**, *25*, 835; (e) Vogel, P.; Auberson, Y. *Helv. Chim. Acta* **1989**, *72*, 278; (f) Malleron, A.; David, S. *New J. Chem.* **1996**, *20*, 153.

5. (a) Antkowiak, T. A.; Sanders, D. C.; Trimitsis, G. B.; Press, J. B.; Shechter, H. *J. Am. Chem. Soc.* **1972**, *94*, 5366; (b) Mehta, G.; Pallavi, K. *Chem. Commun.* **2002**, 2828.

6. All compounds reported here are racemic and all new compounds were characterized on the basis of their IR, <sup>1</sup>H and <sup>13</sup>C NMR and mass spectral data. Selected spectral data: Compound **10**: IR (cm<sup>-1</sup>) 1802; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.04 (s, 1H), 4.56–4.51 (m, 2H), 4.24 (d, *J* = 7.2 Hz, 1H), 3.90 (dd, *J* = 10.8, 5.7 Hz, 1H), 3.72 (t, *J* = 10.5 Hz, 1H), 2.34–2.26 (m, 1H), 1.47 (s, 3H), 1.30 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 107.6, 109.6, 104.5, 73.8, 69.8, 69.4, 60.1, 40.9, 25.9, 25.8 (3C), 24.5, 18.2, -5.5, -5.4; Mass (EI, 70 eV): *m/z* 345 (M+1)<sup>+</sup>. Compound **12**: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 4.58 (dd, *J* = 5.5, 4.0 Hz, 1H), 4.40 (d, *J* = 9.0 Hz, 1H), 4.34 (dd, *J* = 7.5, 5.5 Hz, 1H), 4.06 (d, *J* = 7.0 Hz, 1H), 3.83–3.79 (m, 1H), 3.79 (s, 3H), 3.70 (t, *J* = 10.0 Hz, 1H), 3.47 (s, 3H), 2.12–2.09 (m, 1H), 1.50 (s, 3H), 1.36 (s, 3H), 0.88 (s, 9H), 0.05 (s, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.2, 109.5, 100.6, 74.7, 72.5, 72.2, 59.5, 56.5, 52.4, 43.5, 27.9, 25.8 (3C), 25.6, 18.3, -5.6, -5.5. Compound **14**: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 4.58 (d, *J* = 9.0 Hz, 1H), 4.17 (t, *J* = 3.0 Hz, 1H), 3.90–3.86 (m, 1H), 3.75–3.69 (m, 4H), 3.44 (s, 3H), 3.46 (dd, *J* = 9.5, 3.0 Hz, 1H), 1.73–1.68 (m, 1H); <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD) δ 101.7, 75.3, 70.0, 69.7, 63.3, 60.2, 56.9, 48.9; LRMS: *m/z* 231.1 (M+Na)<sup>+</sup>; HRMS for C<sub>8</sub>H<sub>16</sub>O<sub>6</sub>Na. Calcd: 231.0845. Found: 231.0864. Compound **18**: IR (cm<sup>-1</sup>) 3470, 937; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 5.51 (s, 1H), 5.43 (s, 1H), 5.08 (s, 1H), 4.80 (d, *J* = 6.0 Hz, 1H), 4.16 (t, *J* = 7.2 Hz, 1H), 3.84 (br d, *J* = 10.8 Hz, 1H), 3.71 (br d, *J* = 5.4 Hz, 1H), 3.65–3.60 (m, 1H), 3.53 (s, 3H), 1.50 (s, 3H), 1.38 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 139.0, 117.6, 109.9, 100.3, 75.9, 75.4, 73.3, 63.1, 56.2, 27.7, 25.7; LRMS: *m/z* 253.1052 (M+Na)<sup>+</sup>; HRMS for C<sub>11</sub>H<sub>18</sub>O<sub>5</sub>Na. Calcd: 253.1053. Found: 253.1091. Compound **19**: IR (cm<sup>-1</sup>): 3412; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.93 (s, 1H), 4.41 (d 1/2 ABq, *J* = 7.8, 1.2 Hz, 1H), 4.37 (1/2 ABq, *J* = 8.1 Hz, 1H), 4.27 (dd, *J* = 9.9, 1.8 Hz, 1H), 4.04 (d, *J* = 1.5 Hz, 1H), 3.81 (d, *J* = 9.9 Hz, 1H), 3.54 (s, 3H), 1.53 (s, 3H), 1.38 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 110.9, 98.9, 92.3, 75.7, 75.4, 68.5, 65.0, 55.9, 25.7, 24.5; LRMS: *m/z* 255.0563 (M<sup>+</sup>+Na<sup>+</sup>); HRMS for C<sub>10</sub>H<sub>16</sub>O<sub>6</sub>Na. Calcd: 255.0845. Found: 255.0846. Compound **21**: IR (cm<sup>-1</sup>) 3371; <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 4.42 (d, *J* = 8.7 Hz, 1H), 3.96 (t, *J* = 3.3 Hz, 1H), 3.72 (dd, *J* = 12.0, 1.8 Hz, 1H), 3.63–3.58 (m, 1H), 3.49 (dd as t, *J* = 6.3 Hz, 1H), 3.42 (dd, *J* = 9.6, 2.7 Hz, 1H), 3.37 (s, 3H), 3.25 (dd, *J* = 8.4, 3.3 Hz, 1H); <sup>13</sup>C NMR (75 MHz, D<sub>2</sub>O) δ 101.7, 74.1, 71.6, 70.8, 67.4, 61.7, 57.6; LRMS: *m/z* 217.0528 (M+Na)<sup>+</sup>; HRMS for C<sub>7</sub>H<sub>14</sub>O<sub>6</sub>Na. Calcd: 217.0688. Found: 217.0704.

7. *X-ray data for 15*: X-ray data were collected at 293 K on a SMART CCD-BRUKER diffractometer with graphite monochromated Mo K $\alpha$  radiation ( $\lambda$  = 0.7107 Å). Structure was solved by direct methods (SIR92). Refinement was by full-matrix least-squares procedures on F<sup>2</sup> using SHELXL-97. The nonhydrogen atoms were refined anisotropically whereas hydrogen atoms were refined isotropically. C<sub>16</sub>H<sub>24</sub>O<sub>10</sub>, MW = 376.36, colorless crystal, crystal system: monoclinic, space group: P2(1)/*n*, cell parameters: *a* = 8.9525 (4) Å, *b* = 20.7773 (10) Å, *c* = 11.2568 (5) Å,  $\beta$  = 111.037 (1), *V* = 1954.30 Å<sup>3</sup>, *Z* = 4, *D<sub>c</sub>* = 1.279 g cm<sup>-3</sup>, F(0 0 0) = 800.0,  $\mu$  = 0.11 mm<sup>-1</sup>. Total number of 1.s. parameters = 331, *R*<sub>1</sub> = 0.0472 for 3179 Fo > 4sig(Fo) and 0.0576 for all 3981 data. *wR*<sub>2</sub> = 0.1400, GOF = 1.024, restrained GOF = 1.024 for all data. Crystallographic data has been deposited with Cambridge Crystallographic Data Centre. CCDC 232049. ORTEP diagram of **15** is shown below:



8. Bock, K.; Pedersen, C. *Adv. Carbohydr. Chem. Biochem.* **1983**, *41*, 27.